-
公开(公告)号:US20200292214A1
公开(公告)日:2020-09-17
申请号:US16768171
申请日:2018-12-10
Applicant: University of Kansas
Inventor: Theodore L. Bergman
IPC: F25B21/04
Abstract: Examples of heat exchanger systems for active radiative cooling are described. In one example, the system includes a heat exchanger and a spectrally selective surface material on at least one surface of the heat exchanger. The spectrally selective surface material exhibits high reflectivity at shorter wavelengths and high emissivity at longer wavelengths. The system can also include an active cooling system in some cases to actively transfer heat to the heat exchanger. The use of spectrally selective surfaces that operate at temperatures exceeding that of the outdoor ambient for which convective losses augment radiation losses have advantages over passive cooling, such as but not limited to: providing a better match to cooling loads, reducing the heat rejection surface area required to achieve a desired cooling rate, and increasing the heat transferred to deep space through the atmospheric window so as to simultaneously cool infrastructure, devices, buildings, and Earth.
-
公开(公告)号:US20200214900A1
公开(公告)日:2020-07-09
申请号:US16571854
申请日:2019-09-16
Applicant: University of Kansas
Inventor: Stephen Clifford Waller , Dhaval Bhavsar
Abstract: A barrier system is provided for use in reducing infections associated with post-operative surgical incision and/or a percutaneous medical device, such as a catheter, that is disposed within the surgical incision. Such a barrier system may include: a barrier device having a skin-contacting surface and a catheter-receiving surface; and an adhesive composition configured for adhering to skin, the barrier device, and/or the catheter so as to form a barrier at or adjacent to an incision in the skin where the catheter is percutaneously inserted through the skin. A tensioning anchor and associated system of two or more tensioning anchors is provided for post-operative wound closure. A method for applying and removing the barrier device and tensioning anchors is also provided.
-
公开(公告)号:US20200101132A1
公开(公告)日:2020-04-02
申请号:US16444829
申请日:2019-06-18
Applicant: The University of Kansas
Inventor: Peter S. N. Rowe , Aline Martin , Nicolae Valentin David , M. Laird Forrest , Kenneth Ryan Moulder , Shuang Cai , Daniel J. Aires
IPC: A61K38/16 , A61K9/00 , A61K9/107 , A61K9/127 , A61K8/64 , A61Q7/00 , A61K8/14 , A61K45/06 , A61K31/506 , A61K31/58 , A61K47/10 , A61K47/69
Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.
-
公开(公告)号:US10590157B2
公开(公告)日:2020-03-17
申请号:US16018401
申请日:2018-06-26
Applicant: UNIVERSITY OF KANSAS
Inventor: Brian S. J. Blagg , Bhaskar Reddy Kusuma , Teather Sundstrom
IPC: C07H15/207 , C07H15/203 , C07C211/17
Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
-
公开(公告)号:US10532999B2
公开(公告)日:2020-01-14
申请号:US16149009
申请日:2018-10-01
Applicant: University of Kansas , University of Louisville Research Foundation, Inc. , Southern Research Institute
Inventor: Jennifer Golden , Jeffrey Aube , Donghoon Chung , Chad Schroeder , Tuanli Yao , E. Lucile White , Nichole A. Tower
IPC: C07D409/04 , C07D239/95 , C07D409/12 , C07D403/06 , C07D401/04 , C07D239/91 , C07D239/90 , C07D403/12 , C07D241/06
Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).
-
公开(公告)号:US20190382646A1
公开(公告)日:2019-12-19
申请号:US16527958
申请日:2019-07-31
Applicant: CONOCOPHILLIPS COMPANY , University of Kansas
Inventor: Huili GUAN , Cory BERKLAND , Ahmad MORADI-ARAGHI , Jenn-Tai LIANG , Terry M. CHRISTIAN , Riley B. NEEDHAM , James H. HEDGES , Min CHENG , Faye L. SCULLY
IPC: C09K8/588 , C08F220/56 , C08L33/26 , E21B33/138 , E21B43/16 , C09K8/594
Abstract: The invention is directed to polymers that self-crosslink at acidic pH or can be crosslinked by phenolic agents in brine. Such polymers have lower viscosity and can be pumped deep into reservoirs, where they will cross link in situ, thus increasing their viscosity and/or form a gel and blocking thief zones. Methods of making and using such polymers are also provided.
-
公开(公告)号:US20190352292A1
公开(公告)日:2019-11-21
申请号:US16473878
申请日:2018-01-05
Inventor: John Cijiang HE , Ruijie LIU , Bhaskar DAS , Wenzhen XIAO , Zhengzhe LI , Kyung LEE
IPC: C07D413/04 , C07F5/02 , C07D413/14 , C12N9/99 , A61P13/12
Abstract: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.
-
公开(公告)号:US20190314554A1
公开(公告)日:2019-10-17
申请号:US16428534
申请日:2019-05-31
Applicant: THE UNIVERSITY OF KANSAS
Inventor: Michael DETAMORE , Emily BECK , Stevin GEHRKE , Cory BERKLAND
Abstract: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.
-
公开(公告)号:US20190270730A1
公开(公告)日:2019-09-05
申请号:US16149009
申请日:2018-10-01
Applicant: University of Kansas , University of Louisville Research Foundation, Inc. , Southern Research Institute
Inventor: Jennifer Golden , Jeffrey Aube , Donghoon Chung , Chad Schroeder , Tuanli Yao , E. Lucile White , Nichole A. Tower
IPC: C07D409/04 , C07D239/95 , C07D409/12 , C07D403/06 , C07D241/06 , C07D239/91 , C07D239/90 , C07D403/12 , C07D401/04
Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).
-
公开(公告)号:US20190241612A1
公开(公告)日:2019-08-08
申请号:US16383016
申请日:2019-04-12
Applicant: University of Kansas
Inventor: Jane V. Aldrich , S P Sanjeewa Nilendra Senadheera
IPC: C07K5/12
Abstract: Cyclic tetrapeptide stereochemical isomers of CJ-15,208, pharmaceutical compositions from such cyclic tetrapeptides, and methods of using such pharmaceutical compositions. The cyclic tetrapeptide compounds and pharmaceutical compositions disclosed herein are potent analgesics active in several pain models with generally minimal tolerance and reduced likelihood to induce addiction relative to other known opiates.
-
-
-
-
-
-
-
-
-